This big near term arbitrage here is the valuation disparity between IHL and their US listed peers (Compass, GW Pharma, MindMed and CARA for example).
Each of these would represent a material improvement on the current Aussie valuation of IHL.
Then add even one clinical success and IMO it’s game over, GW Pharma style…